BioSpace News Archive

Drug Development

Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)

The financing will enable Lysogene to accelerate the development of its gene therapy platform.

December 24, 2021
·
7 min read
Drug Development

Convidecia™ Phase III Results Published in The Lancet

CanSino Biologics Inc. today announced that The Lancet[1] published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™).

December 24, 2021
·
4 min read
Business

Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase

Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the “Emerging Company Showcase” that was held earlier this month in New York.

December 24, 2021
·
2 min read
Biotech Bay

Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®

Innovent Biologics, Inc. today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for sintilimab plus bevacizumab biosimilar injection.

December 24, 2021
·
12 min read
COVID-19 Vaccine Developed by WestVac BioPharma Has High Titer Neutralizing Antibodies Against Omicron

WestVac BioPharma Co., Ltd. has achieved a significant progress in the second generation COVID-19 vaccine against the Omicron mutant strain.

December 24, 2021
·
2 min read
Business

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan

Merck and Ridgeback Biotherapeutic today announced that Japan’s Ministry of Health, Labor and Welfare has granted Special Approval for Emergency in Japan for molnupiravir, an investigational oral antiviral medicine, for infectious disease caused by SARS-CoV-2.

December 24, 2021
·
19 min read
Microbix Receives $4.7 Million Order for Viral Transport MediumFollow-on Order from Government of Ontario Procurement Authorities

Microbix Biosystems Inc. announces receipt of a follow-on order of C$ 4.7 million for its viral transport medium (generically known as “ VTM ” and branded “ DxTM™ ” by Microbix). DxTM is a sample-collection device that is essential for PCR-based testing for viruses that cause COVID-19 disease.

December 24, 2021
·
5 min read
Business

Covalon Announces CFO Transition

Covalon Technologies Ltd. today announced that Danny Brannagan , its Chief Financial Officer, will be stepping down in January 2022 to pursue other endeavours.

December 24, 2021
·
2 min read
Business

aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

aTyr Pharma, Inc. today announced the appointment of Danielle Campbell to Vice President, Human Resources.

December 24, 2021
·
5 min read
BioMidwest

Rhaeos, Inc. Raises $2.2 Million in Oversubscribed Seed Round

Rhaeos, Inc. today announced the successful closing of its oversubscribed $2.2 million seed financing.

December 24, 2021
·
3 min read